We have not lifted any functions out of this paper's repositories yet, so there is nothing we have run. If it links a repository, it is listed below.
Some links come from the archived Papers with Code dataset (CC BY-SA 4.0): attribution and licence.
Personalized cancer vaccines are envisioned as the next generation rational cancer immunotherapy. The key step in developing personalized therapeutic cancer vaccines is to identify tumor-specific neoantigens that are on the surface of tumor cells. A promising method for this is through de novo peptide sequencing from mass spectrometry data. In this paper we introduce DeepNovoV2, the state-of-the-art model for peptide sequencing. In DeepNovoV2, a spectrum is directly represented as a set of (m/z, intensity) pairs, therefore it does not suffer from the accuracy-speed/memory trade-off problem. The model combines an order invariant network structure (T-Net) and recurrent neural networks and provides a complete end-to-end training and prediction framework to sequence patterns of peptides. Our experiments on a wide variety of data from different species show that DeepNovoV2 outperforms previous state-of-the-art methods, achieving 13.01-23.95\% higher accuracy at the peptide level.
The same record, over MCP at https://syntology.ai/mcp:
get_harvested_code_for_paper("1904.08514")
get_code_for_paper("1904.08514")
have("1904.08514")
Connect an agent — have() is free.